{"schema_version":"secwatch.filing_event.v1","accession":"0001787306-24-000078","form_type":"8-K","ticker":"ARQT","cik":"0001787306","company_name":"Arcutis Biotherapeutics, Inc.","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.114079+00:00","generated_at":"2026-06-02T01:04:38.492440+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Arcutis Q1 product revenue $21.6M up 675% YoY; net loss narrows to $35.4M","bullets":["Q1 product revenue $21.6M ($15M cream, $6.5M foam) vs $2.8M in Q1 2023; 59% QoQ growth.","Net loss $35.4M ($0.32/sh) vs $80.1M ($1.31/sh) in Q1 2023; cash $404.5M at March 31.","PDUFA date July 7, 2024 for roflumilast cream 0.15% in atopic dermatitis (ages 6+).","Completed $172.5M public offering in February; licensing deal with Sato Pharma for Japan.","Appointed David Topper CFO effective April 10, 2024; sNDA for scalp/body psoriasis expected Q3 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001787306-24-000078","json":"https://secwatch.observer/filing/0001787306-24-000078.json","markdown":"https://secwatch.observer/filing/0001787306-24-000078.md","text":"https://secwatch.observer/filing/0001787306-24-000078.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787306/000178730624000078/0001787306-24-000078-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787306/000178730624000078/arqt-20240514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T01:04:38.492440+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2e99932c7f2abc5451b0c92a84e726735050385c","claim":"Arcutis Biotherapeutics, Inc. reported the quarter ended March 31, 2024 results: revenue $21.6 million.","evidence_excerpt":"3027 Townsgate Road, Suite 300 Westlake Village, CA 91361 | arcutis.com First Quarter 2024 Summary Financial Results Product revenues for the quarter ended March 31, 2024 were $21.6 million compared to $2.8 million for the corresponding period in 2023. Revenues for the quarter were $15.0 million for ZORYVE (roflumilast) cream 0.3% and $6.5 million for ZORYVE","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730624000078/0001787306-24-000078-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Revenue","value":"$21.6 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}